SCHEMBL5010041

SCHEMBL5010041

CCN(C(=O)[CH]c1ccccc1)C(C)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PGR P06401 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
KCNH2 Q12809 1/20 0.41
MDM2 Q00987 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
AKR1C3 P42330 1/20 0.35
ALOX5 P09917 1/20 0.35
LMNA P02545 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4982102 0.84 L3MBTL1 (0.47) NPC1L3MBTL1PGRADRA2AADRA2B
SCHEMBL5665183 0.79 KDM4E (0.36) NPC1L3MBTL1PGRKCNH2MEN1
SCHEMBL4986792 0.74 NPC1 (0.47) NPC1L3MBTL1TRPM8MEN1KMT2A
SCHEMBL7215103 0.73 L3MBTL1 (0.68) NPC1L3MBTL1TRPM8MEN1KMT2A
SCHEMBL7220837 0.73 NPC1 (0.44) NPC1L3MBTL1TRPM8MEN1KMT2A
SCHEMBL4991698 0.72 L3MBTL1 (0.53) NPC1L3MBTL1TRPM8LTB4RLTB4R2
SCHEMBL4986055 0.72 NPC1 (0.51) NPC1L3MBTL1MEN1KMT2AAKR1C3
SCHEMBL5664989 0.70 L3MBTL1 (0.50) NPC1L3MBTL1LMNAALDH1A1HPGD
SCHEMBL27171238 0.69 MEN1 (0.57) NPC1L3MBTL1MEN1KMT2ALMNA
SCHEMBL4667661 0.69 ALDH1A1 (0.47) PGRADRA2AADRA2BHTR2AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468378-B2 Substituted quinoline compounds PFIZER INC. (US) 2008-12-23 US disclosed
EP-1716137-A1 SUBSTITUTED QUINOLINE COMPOUNDS Pfizer Products Incorporated (US) 2006-11-02 EP disclosed
US-20050234099-A1 Substituted quinoline compounds PFIZER INC 2005-10-20 US disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234099-A1 Substituted quinoline compounds APOB, APOL1, MTPN NPC1 32/4885L3MBTL1 1827/4885PGR 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.